Credit Brief — Shenzhen New Industries Biomedical Engineering Co., Ltd. (新产业)
300832.SZ · Shenzhen ChiNext · Data window: 2022–2026 H1 · Sources: official periodic reports filed via cninfo (巨潮资讯网)
All figures are extracted mechanically from official filings and are traceable to source page (see §9). Narrative sections are analyst commentary; mechanical sections are produced without any LLM. Not investment advice. Not a credit rating.
1. Identity & legitimacy
- Legal representative: 饶微
- Registered address: 深圳市坪山区坑梓街道金沙社区锦绣东路 23 号新产业生物大厦二十一层
- Office address: 深圳市坪山区坑梓街道金沙社区锦绣东路 23 号新产业生物大厦
- Actual controller: 翁先定
- Employees: 2,841
Source: identity fields above are mechanically extracted from the issuer's own filed annual reports. - Registration data via corporate registry is not included in this build
2. Compliance & legal
Compliance screens (dishonest debtor / enforcement / penalties / business exceptions) require a registry data source not included in this build
3. Business profile
Top customer/supplier tables not generated for this issuer.
4. Financial dashboard (CNY mn)
Assets
| 2022 | 2023 | 2024 | 2025 | 2026 H1 | |
|---|---|---|---|---|---|
| Cash and bank balances | 483.4 | 1,048.3 | 919.5 | 997.4 | 1,454.1 |
| Trading financial assets | 2,813.7 | 2,080.2 | 1,723.5 | 1,266.8 | 678.6 |
| Accounts receivable | 474.7 | 620.5 | 950.1 | 990.0 | 994.6 |
| Other receivables | 5.9 | 6.5 | 6.9 | 7.8 | 9.7 |
| Inventories | 839.3 | 916.8 | 1,198.0 | 1,040.0 | 1,048.3 |
| Long-term equity investments | 12.9 | 117.1 | 126.4 | 196.3 | 196.3 |
| Fixed assets | 716.2 | 1,266.3 | 1,274.1 | 1,208.5 | 1,149.7 |
| Construction in progress | 605.7 | 169.3 | 414.6 | 549.5 | 649.1 |
| Intangible assets | 172.5 | 169.5 | 245.1 | 237.4 | 230.2 |
| Total assets | 7,014.6 | 8,222.5 | 9,619.5 | 9,940.8 | 9,763.9 |
Liabilities
| 2022 | 2023 | 2024 | 2025 | 2026 H1 | |
|---|---|---|---|---|---|
| Short-term borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Notes payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accounts payable | 176.7 | 127.0 | 456.6 | 152.1 | 199.2 |
| Contract liabilities | 108.9 | 91.5 | 80.1 | 87.7 | 70.5 |
| Other payables | 82.8 | 89.3 | 84.0 | 91.8 | 98.4 |
| Current portion of non-current liabilities | 1.3 | 1.7 | 1.3 | 1.8 | 2.0 |
| Long-term borrowings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bonds payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total liabilities | 615.1 | 678.1 | 1,042.8 | 795.9 | 794.8 |
Equity
| 2022 | 2023 | 2024 | 2025 | 2026 H1 | |
|---|---|---|---|---|---|
| Paid-in capital | 786.1 | 785.7 | 785.7 | 785.7 | 785.7 |
| Capital reserve | 1,348.3 | 1,332.4 | 1,332.4 | 1,332.4 | 1,332.4 |
| Retained earnings | 3,874.3 | 4,980.7 | 6,023.9 | 6,622.7 | 6,549.9 |
| Equity attributable to owners of the parent | 6,399.5 | 7,544.4 | 8,576.6 | 9,144.9 | 8,969.1 |
| Minority interests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total equity | 6,399.5 | 7,544.4 | 8,576.6 | 9,144.9 | 8,969.1 |
Income statement
| 2022 | 2023 | 2024 | 2025 | 2026 H1 | |
|---|---|---|---|---|---|
| Revenue | 3,047.0 | 3,929.7 | 4,535.4 | 4,576.8 | 2,420.3 |
| Cost of sales | 906.2 | 1,062.5 | 1,266.5 | 1,407.2 | 704.7 |
| Selling expenses | 458.8 | 630.3 | 714.6 | 736.6 | 364.6 |
| Administrative expenses | 4.9 | 107.0 | 125.3 | 127.0 | 60.7 |
| Finance costs | -72.5 | -30.5 | -34.7 | -18.6 | 52.6 |
| Investment income | 61.3 | 74.4 | 89.5 | 57.4 | 35.9 |
| Operating profit | 1,503.6 | 1,895.4 | 2,111.2 | 1,882.7 | 991.3 |
| Profit before tax | 1,501.2 | 1,893.1 | 2,093.2 | 1,855.3 | 989.7 |
| Net profit | 1,327.9 | 1,653.7 | 1,828.5 | 1,620.3 | 867.7 |
5. Ratios
| Ratio | 2022 | 2023 | 2024 | 2025 | 2026 H1 |
|---|---|---|---|---|---|
| Current ratio | 8.26x | 8.56x | 5.56x | 8.98x | 9.13x |
| Quick ratio | 6.82x | 7.01x | 4.25x | 7.34x | 7.47x |
| Debt-to-asset ratio | 8.8% | 8.2% | 10.8% | 8.0% | 8.1% |
| Total debt / EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| EBITDA interest coverage | 22.58x | 66.72x | 64.69x | 107.85x | 21.96x |
| Gross margin | 70.3% | 73.0% | 72.1% | 69.3% | 70.9% |
| Net margin | 43.6% | 42.1% | 40.3% | 35.4% | 35.9% |
| Return on equity (ROE) | 20.8% | 21.9% | 21.3% | 17.7% | 9.7% |
| Revenue growth | — | 29.0% | 15.4% | 0.9% | -47.1% |
| Net profit growth | — | 24.5% | 10.6% | -11.4% | -46.4% |
| Receivable days | 57 | 58 | 76 | 79 | 150 |
| Cash received / revenue | 95.0% | 96.8% | 93.4% | 103.1% | 103.8% |
| Operating CF / net profit | 0.72x | 0.86x | 0.74x | 0.94x | 1.04x |
| Free cash flow | 361.6 | 1,094.9 | 642.1 | 1,040.1 | 1,535.7 |
Mechanical risk flags
- ⚠ Debt-to-asset ratio: 0.08 (level: high, reference threshold: <0.65)
6. Cross-check flags (mechanical reconciliation)
- 2023 · Cash-flow statement net increase vs balance-sheet cash movement: 567.7 vs 564.8 CNY mn (deviation 0.5%, severity low)
Sources: 2023年年度报告.pdf p.101 「五、现金及现金等价物净增加额」 vs 2023年年度报告.pdf p.92 「货币资金」. CF-statement figure above the balance-sheet movement by 2.8 CNY mn — typical causes are restricted-cash release or cash-equivalent scope changes; flagged for analyst review. - 2024 · Cash-flow statement net increase vs balance-sheet cash movement: -126.2 vs -128.7 CNY mn (deviation 1.93%, severity mid)
Sources: 2024年年度报告.pdf p.94 「五、现金及现金等价物净增加额」 vs 2024年年度报告.pdf p.85 「货币资金」. CF-statement figure above the balance-sheet movement by 2.5 CNY mn — typical causes are restricted-cash release or cash-equivalent scope changes; flagged for analyst review. - 2025 · Cash-flow statement net increase vs balance-sheet cash movement: 76.5 vs 77.9 CNY mn (deviation 1.81%, severity mid)
Sources: 2025年年度报告.pdf p.88 「五、现金及现金等价物净增加额」 vs 2025年年度报告.pdf p.79 「货币资金」. CF-statement figure below the balance-sheet movement by 1.4 CNY mn — typical causes are restricted-cash release or cash-equivalent scope changes; flagged for analyst review. - 2026Q2 · Cash-flow statement net increase vs balance-sheet cash movement: 458.1 vs 456.7 CNY mn (deviation 0.31%, severity low)
Sources: 2026年半年度报告.pdf p.57 「五、现金及现金等价物净增加额」 vs 2026年半年度报告.pdf p.47 「货币资金」. CF-statement figure above the balance-sheet movement by 1.4 CNY mn — typical causes are restricted-cash release or cash-equivalent scope changes; flagged for analyst review.
4 check(s) not run for missing inputs: 前五大应收 vs BS 应收账款; 前五大其他应收 vs BS 其他应收款; 前五大预付 vs BS 预付款项; 授信表内总合计 vs Σ机构行.
Premium tier. The analyst red-flag review and the industry-context commentary (sections 7–8 of the full brief) are not included in this free build. Join the waitlist for early access.
9. Method & provenance
All financial figures above were extracted mechanically from the company's official periodic reports (unit-normalized to CNY). Each key figure carries cell-level provenance — source file, page and original line item. Samples (latest annual period):
| Item | Period | Value (CNY mn) | Source file | Page | Raw line item | Raw value (as filed) |
|---|---|---|---|---|---|---|
| Cash and bank balances | 2025 | 997.4 | 2025年年度报告.pdf | 79 | 货币资金 | 997437173.52 (元) |
| Total assets | 2025 | 9,940.8 | 2025年年度报告.pdf | 80 | 资产总计 | 9940757976.79 (元) |
| Accounts receivable | 2025 | 990.0 | 2025年年度报告.pdf | 79 | 应收账款 | 989988955.09 (元) |
| Fixed assets | 2025 | 1,208.5 | 2025年年度报告.pdf | 80 | 固定资产 | 1208482317.98 (元) |
| Short-term borrowings | 2025 | 0.0 | 2025年年度报告.pdf | 80 | 短期借款 | 0.0 (元) |
This brief is built solely on officially filed public disclosures. It is not investment advice, not a credit rating, and not an offer of any service. Figures may contain extraction or caliber effects; verify against the original filings before relying on them.